Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 89

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 89
---
ated Financial Information OmnigenicsAI is providing the following unaudited pro forma combined consolidated financial information to aid you in your analysis of the financial aspects of the Transactions. The following unaudited pro forma combined statements of financial position as of June 30, 2024, combines the historical unaudited balance sheet of APx as of June 30, 2024 and the historical audited combined statement of financial position of the Company as of June 30, 2024, giving pro forma effect to the Business Combination, as of June 30, 2024. The following unaudited pro forma combined statement of operations for the year ended June 30, 2024, combine: •the historical audited combined statement of operations of OmnigenicsAI for year ended June30, 2024; and •the historical statement of operations of APx for the twelve -monthperiod ended June30, 2024, using its unaudited statements of operations for the six -monthperiod ended June30, 2024, together with its audited statements of operations for the fiscal year ended December31, 2023, deducting its unaudited statements of operations for the six -monthperiod ended June30, 2023. The unaudited pro forma combined consolidated statement of operations was prepared giving pro forma effect to the Business Combination as if it had occurred on July 1, 2023, the beginning of the earliest period presented. For more information about the Business Combination see the section titled “ The Business Combination.” The unaudited pro forma condensed combined consolidated financial information has been prepared assuming: • Scenario 1 — Assuming no redemptions for cash: This presentation assumes that no SPAC Shareholders exercise redemption rights with respect to their SPAC Ordinary Shares upon consummation of the Business Combination; and considers that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” • Scenario 2 — Assuming redemptions of 50% of the outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to 50% of Public Shares upon consummation of the Business Combination at a redemption price of approximately $11.60 per share as of June30, 2024. Scenario 2 includes all adjustments contained in Scenario 1 and presents additional adjustments to